At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
REP 2139-Ca +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
In Brief
A Phase 2 clinical trial evaluating REP 2139-Ca, pegylated interferon, and 1 other intervention for Hepatitis B, Chronic. Completed, enrolled 5 participants.
Detailed Summary
The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already receiving entecavir and continuing entecavir with treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedApr 2016
Primary CompletionSep 2016
Study CompletionDec 2016
TodayJul 2026
First PostedApr 4, 2016
Enrollment StartOct 1, 2012
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.2 years ago
Interventions
REP 2139-Cadrug
the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferondrug
immunotherapy
entecavirdrug
local generic entecavir